U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799559) titled 'Study on the Efficacy and Safety of QLM1016 in Schizophrenia' on Jan. 23.
Brief Summary: The study will evaluate the antipsychotic efficacy of QLM1016 in a multicenter, randomized, double-blind, parallel controlled study in patients diagnosed with schizophrenia.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: 3-6mg QLM1016
3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
DRUG: 10-20 mg Aripiprazole oral solution film
10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once dai...